MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4081/aiua.2026.14731

Медицинская библиотека · Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica · 2026

Prognostic value of Ki67 and PSA-immunostaining in de novo metastatic hormone-sensitive prostate cancer.

Ferreira Ana Marta, Jarimba Roberto, Rego André, Gama João, Almeida Rui, Eliseu Miguel, Quaresma Vasco, Nunes Pedro, Sousa Vitor, Figueiredo Arnaldo

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Prostate cancer comprises biologically distinct subtypes. Ki67 reflects tumour proliferation, while prostate-specific antigen immunostaining (PSA-IHC) indicates differentiation, with low PSA-IHC suggesting dedifferentiation. The prognostic role of these markers in de novo metastatic hormone-sensitive prostate cancer (mHSPC) remains unclear.

AIM: To evaluate the prognostic value of Ki67 and PSA-IHC, individually and combined, in de novo mHSPC, and explore their relevance across treatment modalities.

METHODS

We retrospectively analysed patients diagnosed with de novo mHSPC (2015-2020) who ultimately died from prostate cancer. Clinical data included age, ISUP grade, baseline and 7-month PSA, metastatic sites, and first-line treatment. Ki67 (MIB-1) and PSA-IHC were quantified as the percentage of positive nuclei and cytoplasmic staining, respectively. The 75th percentile defined high vs low expression. Endpoints were biochemical (bPFS), radiological (rPFS), castration-resistant progression-free survival (CRPC-FS), and overall survival (OS). Exploratory analyses were performed by treatment type: androgen receptor pathway inhibitors (ARPIs) or taxanes.

RESULTS

Sixty-seven patients were included (median age 77 years). Most had high-grade tumours (ISUP ≥3, 83.6%). High Ki67 (>P75) correlated with shorter OS (10 vs 21 months, p=0.013). PSA-IHC >P75 predicted longer bPFS (13 vs 9 months, p=0.027). Combined stratification identified distinct prognostic groups (p=0.034): PSA-IHC low/Ki67 high defined a high-risk phenotype with poor outcomes, particularly among taxane-treated patients (p=0.006).

CONCLUSIONS

Combined Ki67 and PSA-IHC assessment refines risk stratification in de novo mHSPC, identifying a high-risk PSA-IHC low/Ki67 high subgroup with markedly worse prognosis. These findings warrant prospective validation.

Для цитирования: Ferreira Ana Marta, Jarimba Roberto, Rego André, Gama João, Almeida Rui, Eliseu Miguel, Quaresma Vasco, Nunes Pedro, Sousa Vitor, Figueiredo Arnaldo. Prognostic value of Ki67 and PSA-immunostaining in de novo metastatic hormone-sensitive prostate cancer.. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica. 2026. DOI: 10.4081/aiua.2026.14731.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.